The current valuation score of Novavax Inc is 8.67, ranking 71 out of 385 in the Biotechnology & Medical Research industry. Its current P/E ratio is -13.06, which is -136.22% below the recent high of 4.73 and -51.50% above the recent low of -19.79.
P/E
Relevant data have not been disclosed by the company yet.
P/B
Relevant data have not been disclosed by the company yet.
P/S
Relevant data have not been disclosed by the company yet.
P/CF
Relevant data have not been disclosed by the company yet.